Two patents currently held, every record listed here
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2034. from the record
Of the 1 now held by other companies, 1 name Propel Air Biopharma LLC as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2034
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2037.
US 11,744,838
Methods of Treating Hypogonadism with Transnasal Testosterone Bio-Adhesive Gel Formulations in Male with Allergic Rhinitis, and Methods for Preventing an Allergic Rhinitis Event
Mar 17, 2034
US 11,090,312
Methods of Treating Hypogonadism With Transnasal Testerosterone Bio-Adhesive Gel Formulations in Male With Allergic Rhinitis, And Methods for Preventing An Allergic Rhinitis Event
Mar 17, 2034
202420272030203320362037
2 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Feb 2037 · High confidence
Granted 2023. Computed term ends 2037.
now held by Propel-Air Biopharma, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 5, 2027The maintenance fee for Methods of Treating Hypogonadism with Transnasal Testosterone Bio-Adhesive Gel Formulations in Male with Allergic Rhinitis, and Methods for Preventing an Allergic Rhinitis Event (US 11,744,838) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,090,312 | Methods of Treating Hypogonadism With Transnasal Testerosterone Bio-Adhesive Gel Formulations in Male With Allergic Rhinitis, And Methods for Preventing An Allergic Rhinitis Event In force · Medium confidence | In force | Medium confidence | |
| US 11,744,838 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-Adhesive Gel Formulations in Male with Allergic Rhinitis, and Methods for Preventing an Allergic Rhinitis Event In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 2: 1 patent in force now held by others · 4 patents ended · 2 applications pending · 19 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.